Gender-specific aspects of oncological diseases: focus on stomach cancer and colorectal cancer

Cover Page

Cite item

Full Text

Abstract

With each passing day, medicine strives to become more personalized, centered directly on the patient. A significant aspect of this dynamic involves the consideration of patients' gender, which influences their physiology, the pathogenesis of developing diseases, and their response to treatment.

Historically, most research has been conducted on male cells, male mice, and men, with women of childbearing age often excluded from studies for their safety. It was assumed that female cells were identical to male cells, leading medical research to be predominantly focused on male physiology. However, this approach was fundamentally flawed, as individuals of different sexes differ in terms of epidemiology, pathogenesis, clinical manifestations, disease progression, and responses to treatment. Knowledge of these gender-specific characteristics can aid clinicians in their patient management.

This literature review aims to examine the peculiarities of cancer progression in men and women, specifically in the cases of stomach and colorectal cancer.

About the authors

Ilgiz G. Gataullin

Kazan State Medical Academy

Email: ilgizg@list.ru
ORCID iD: 0000-0001-5115-6388

PhD, Professor, Department of Oncology, Radiology and Palliative Medicine

Russian Federation, Kazan

Rishat M. Dinov

Kazan State Medical Academy

Email: rishatdinov@mail.ru
ORCID iD: 0009-0000-8570-5904

oncologist and a Resident of the Department of Oncology, Radiology and Palliative Medicine

Russian Federation, Kazan

Bulat I. Gataullin

Kazan State Medical Academy; Kazan (Volga region) Federal University

Author for correspondence.
Email: bulatg@list.ru
ORCID iD: 0000-0003-1695-168X

PhD, Associate professor, Department of Surgery at the Institute of Fundamental Medicine and Biology

Russian Federation, Kazan; Kazan

Yana А. Erpert

Kazan State Medical Academy

Email: yana.erpert@bk.ru
ORCID iD: 0009-0007-0937-928X

resident of the Department of Oncology, Radiology and Palliative Medicine

Russian Federation, Kazan

References

  1. Kaprin AD, Starinsky VV, Shakhzadova AO. The state of cancer care for the population of Russia in 2022. M., 2022. (In Russ.). [Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2022 году. М., 2022].
  2. Rubin JB. The spectrum of sex differences in cancer. Trends Cancer. 2022;8(4):303-315. https://doi.org/10.1016/j.trecan.2022.01.013
  3. McCartney G, Mahmood L, Leyland AH, et al. Contribution of smoking-related and alcohol-related deaths to the gender gap in mortality: evidence from 30 European countries. Tob Control. 2011;20:166-68. https://doi.org/10.1136/tc.2010.037929
  4. Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16:330-39. https://doi.org/10.1038/nrc.2016.30
  5. Wagner AD, Oertelt-Prigione S, Adjei A, et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019;30:1912-1924. https://doi.org/10.1093/annonc/mdz414
  6. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
  7. Abolfazl A, Sara A, Seidamir PT, et al. Overview of epidemiological characteristics, clinical features, and risk factors of gastric cancer in Asia-Pacific region. Asia Pac J Clin Oncol. 2022;18(6):493-505. https://doi.org/10.1111/ajco.13654
  8. Deng W, Jin L, Zhuo H. Alcohol consumption and risk of stomach cancer: A meta-analysis. Chem Biol Interact. 2021;336:109365. https://doi.org/10.1016/j.cbi.2021.109365
  9. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology. 2015, 10th ed. Philadelphia, PA: Wolters Kluwer.
  10. Waldum HL, Fossmark R. Types of Gastric Carcinomas. Int J Mol Sci. 2018;19(12):4109. https://doi.org/10.3390/ijms19124109
  11. Yao Q, Qi X, Xie SH. Sex difference in the incidence of cardia and non-cardia gastric cancer in the United States, 1992-2014. BMC Gastroenterol. 2020;20(1):418. https://doi.org/10.1186/s12876-020-01551-1
  12. Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187-1203. https://doi.org/10.3748/wjg.v28.i12.1187
  13. Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-713. https://doi.org/10.1158/1055-9965.EPI-13-1057
  14. Colquhoun A, Arnold M, Ferlay J, et al. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881-1888. https://doi.org/10.1136/gutjnl-2014-308915
  15. Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44(16):2397-2403. https://doi.org/10.1016/j.ejca.2008.07.031
  16. Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58(1):16-23. https://doi.org/10.1136/gut.2008.161331
  17. Rutegard M, Shore R, Lu Y, Lagergren P, et al. Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer. 2010;46(6):1093-1100. https://doi.org/10.1016/j.ejca.2010.01.029
  18. Luan X, Niu P, Wang W, et al. Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. J Oncol. 2022:1269435. https://doi.org/10.1155/2022/1269435
  19. Hsu LW, Huang KH, Chen MH, et al. Genetic alterations in gastric cancer patients according to sex. Aging. 2020;13(1):376-388. https://doi.org/10.18632/aging.202142
  20. Kohlruss M, Ott K, Grosser B, et al. Sexual difference matters: females with high microsatellite instability show increased survival after neoadjuvant chemotherapy in gastric cancer. Cancers. 2021;13(5):1048. https://doi.org/10.3390/cancers13051048
  21. Kalff MC, Wagner AD, Verhoeven RHA, et al. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer. 2022;25(1):22-32. https://doi.org/10.1007/s10120-021-01225-1
  22. Lee SS, Ryu SW, Kim IH, Sohn SS. Impact of gender and body mass index on surgical outcomes following gastrectomy: an Asia-Pacific perspective. Chinese Medical Journal. 2012;125(1):67-71. PMID: 22340468
  23. Park HC, Shin A, Kim BW, et al. Data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry. Ann Coloproctol. 2013;29(4):144-149. https://doi.org/10.3393/ac.2013.29.4.144
  24. Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211-219. https://doi.org/10.1001/jamaoncol.2016.4227
  25. Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61(1):126-130. PMID: 11196149
  26. Quaas A, Biesma HD, Wagner AD, Verheij M, et al. Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts. Eur J Cancer. 2022;173:95-104. https://doi.org/10.1016/j.ejca.2022.06.025
  27. Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis. 2013;28(12):1637-1642. https://doi.org/10.1007/s00384-013-1715-8
  28. Wiencke JK, Zheng S, Lafuente A, et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(6):501-506. PMID: 10385139
  29. Liao H, Li C, Ai Y, Kou Y. Gut microbiome is more stable in males than in females during the development of colorectal cancer. J Appl Microbiol. 2021;131(1):435-448. https://doi.org/10.1111/jam.14943
  30. Baraibar I, Ros J, Saoudi N, et al. Sex and gender perspectives in colorectal cancer. ESMO Open. 2023;8(2):101204. https://doi.org/10.1016/j.esmoop.2023.101204
  31. Prado CMM, Baracos V, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-3268. https://doi.org/10.1158/1078-0432.CCR-06-3067
  32. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283. https://doi.org/10.1016/0006-2952(92)90010-g
  33. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet. 2003;42:779-791. https://doi.org/10.2165/00003088-200342090-00001
  34. Micheli A, Ciampichini R, Oberaigner W, et al. EUROCARE Working Group. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-27. https://doi.org/10.1016/j.ejca.2008.11.008
  35. Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 2010;21(10):2023-2028. https://doi.org/10.1093/annonc/mdq067
  36. Cristina V, Mahachie J, Mauer M, et al. Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group. JAMA Oncol. 2018;1;4(7):1003-1006. https://doi.org/10.1001/jamaoncol.2018.1080
  37. Davidson M, Wagner AD, Kouvelakis K, et al. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. Eur J Cancer. 2019;121: 40-47. https://doi.org/10.1016/j.ejca.2019.08.010
  38. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175. https://doi.org/10.1200/JCO.1992.10.7.1171
  39. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;15:1491-1498. https://doi.org/10.1200/JCO.2002.20.6.1491
  40. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol. 2010;10:4086-4093. https://doi.org/10.1200/JCO.2009.27.0579
  41. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-fluorouracil Toxicity Study Group. J Clin Oncol. 2008;26:2131-2138. https://doi.org/10.1200/JCO.2006.10.4182
  42. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165-1171. https://doi.org/10.1002/cncr.20878
  43. Yamada Y, Koizumi W, Nishikawa K, et al. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Cancer Sci. 2019;110(9):2875-2883. https://doi.org/10.1111/cas.14117
  44. Ros-Montana FJ, Navarro V, Comas C, et al. Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib. Ann Oncol. 2022;33(7): S136-S196. https://doi.org/10.1016/j.annonc.2022.07.512
  45. Wallis CJD, Butaney M, Satkunasivam R, et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5(4):529-536. https://doi.org/10.1001/jamaoncol.2018.5904
  46. Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737-746. https://doi.org/10.1016/S1470-2045(18)30261-4
  47. Ye Y, Jing Y, Li L, et al. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 2020;11(1):1779. https://doi.org/10.1038/s41467-020-15679-x
  48. Unger JM, Vaidya R, Albain KS, et al. Sex Differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474-1486. https://doi.org/10.1200/JCO.21.02377
  49. Duma N, Abdel-Ghani A, Yadav S, et al. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? The Oncologist. 2019;24(11):e1148-e1155. https://doi.org/10.1634/theoncologist.2019-0094
  50. Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine. 2018;16:94-94. https://doi.org/10.1186/s12967-018-1467-x
  51. Jing Y, Zhang Y, Wang J, et al. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. JNCI. 2021;113(10):1396-1404. https://doi.org/10.1093/jnci/djab035
  52. Owen DH, Wei L, Bertino EM, et al. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer. Clinical Lung Cancer. 2018;19(6):e893-e900. https://doi.org/10.1016/j.cllc.2018.08.008
  53. Wilcox NS, Rotz SJ, Mullen M, et al. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circ Res. 2022;130(4):632-651. https://doi.org/10.1161/CIRCRESAHA.121.319901

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Gataullin I.G., Dinov R.M., Gataullin B.I., Erpert Y.А.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».